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Membrane transport probably participates in the lifecycle of hepatitis C virus (HCV).  Rab proteins are 
essential host factors for HCV RNA replication,  but these proteins’ roles in other steps of the HCV 
lifecycle are not clear.  The tight junction (TJ) plays a key role in HCV infection.  Rab13 regulates the 
endocytic recycling of the TJ-associated proteins.  Here we investigated whether Rab13 is involved in 
the HCV entry step.  We used HuH-7-derived RSc cells and Li23-derived D7 cells.  To evaluate the eﬀ ect 
of Rab13 in HCV infection,  we transfected the cells with siRNA targeting Rab13 before HCV infection.  
The down-regulation of Rab13 inhibited HCV infection.  The D7 cells had showed a greater inhibitory 
eﬀ ect against HCV infection compared to that in the RSc cells by Rab13 knockdown.  Next,  to evaluate 
the eﬀ ect of Rab13 after infection,  we inoculated the cells with HCV before transfection of the siRNA.  
The down-regulation of Rab13 did not show any eﬀ ects after HCV infection.  We further examined 
whether Rab13 would inﬂ uence HCV RNA replication by using HCV replicon-harboring cells.  The 
results revealed that Rab13 did not aﬀ ect the step of HCV RNA replication.  These results suggest that 
Rab13 plays an important role in the step of HCV entry.
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H epatitis C virus (HCV) causes chronic hepatitis and can progresses to fatal liver cirrhosis and 
hepatocellular carcinoma.  The exclusion of the virus 
is thus a strategy for preventing the progress of the 
disease after HCV infection.  HCV belongs to the 
Flaviviridae family.  The genome of HCV is a single-
stranded 9.6-kb RNA.  The genome encodes a single 
polyprotein of 3,000 amino acids.  The host and viral 
protease cleave the polyprotein into 10 mature proteins:
Core,  envelope 1 (E1),  E2,  p7,  nonstructural 2 (NS2),  
NS3,  NS4A,  NS4B,  NS5A and NS5B [1-3].
　 The HCV entry into cells consists of several steps 
[4].  The ﬁ rst attachment of HCV particles onto the 
cell surface require host factors,  such as glycosami-
noglycans and low-density lipoprotein receptor [5,  6].  
Then,  HCV E2 binds to the cell surface receptors:
scavenger receptor class B type I (SR-BI) and CD81 
[7-10].  CD81 and SR-BI act as the binding receptors 
for HCV infection.  CD81-HCV complexes then inter-
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act with claudin1 (CLDN1) and occludin (OCLN).  
CLDN1 and OCLN are the main tight junction (TJ) 
proteins and act as the entry receptors for HCV infec-
tion.  After interaction with these TJ proteins,  HCV 
complexes are internalized via endocytosis.
　 We reported that statins,  which are HMG-CoA 
reductase inhibitors,  suppressed HCV RNA replica-
tion via inhibition of the biosynthesis of geranylgera-
nyl pyrophosphate (GGPP) [11].  Rabs need modiﬁ ca-
tion with GGPP for their activation by geranyl
geranyltransferase II.  We have therefore tried to 
clarify the eﬀ ect of Rabs in each step of the HCV 
lifecycle.
　 The Rab proteins belong to the Ras superfamily of 
small GTPases.  The Rab family consists of more than 
60 subtypes.  As membrane transport plays a signiﬁ -
cant role in various steps in the HCV lifecycle,  the 
Rab proteins seem to be essential host factors for 
HCV infection,  replication,  and assembly.  For 
example,  Rab5 and Rab7 are important for HCV RNA 
replication,  and Rab18 is required for viral assembly 
[12-15].
　 However,  there is apparently no prior study about 
Rabs regarding the entry step of HCV.  CLDN1 and 
OCLN are the entry receptors for HCV infection,  
and the membrane traﬃ  cking of them is regulated by 
Rab13 [16,  17].  The Rab13 translocates the TJ 
proteins to cytoplasmic vesicles and recycles them to 
the TJ.
　 The genotype 2a JFH-1 strain produces robust 
infectious HCV in cell culture [18].  To clarify the 
role of Rab13 in the HCV lifecycle,  we used our 
developed HCV-JFH-1 reporter system [19].  Here,  
we investigated whether Rab13 is essential in the HCV 
entry step.
Materials and Methods
　 Cell culture and HCV RNAs. RSc is a clonal 
cell line from the human hepatoma cell line HuH-7.  
We cultured RSc cells in Dulbecco’s modiﬁ ed Eagle’s 
medium (DMEM; Life Technologies,  Carlsbad,  CA,  
USA) supplemented with 10  fetal bovine serum 
(FBS) (Life Technologies) [19].  D7 is a clonal cell 
line from the human hepatoma cell line Li23 [19].  We 
maintained D7 cells in F12 medium (Life Technologies) 
and DMEM (1 : 1 in volume) supplemented with 1  
FBS and epidermal growth factor (50ng/ml; Pepro 
Tech,  Rocky Hill,  NJ).  The subgenomic HCV-JFH-1 
replicon contains Renilla luciferase (RL) and neomycin 
phosphotransferase genes in the ﬁ rst cistron and NS3 
to NS5B region of HCV-JFH-1 in the second cistron 
[20].  The subgenomic HCV-JFH-1 replicon-harboring 
cells were cultured in the above medium supplemented 
with G418 (0.3mg/ml; Geneticin,  Invitrogen,  Carlsbad,  
CA,  USA).
　 siRNA. We introduced small interfering RNAs 
(siRNAs) targeting Rab13 (M-008389-00,  Thermo 
Fisher Scientiﬁ c,  Wilmington,  DE,  USA) or control 
siRNAs (D-001206-13-20,  Thermo Fisher Scientiﬁ c) 
into RSc and D7 cells by using Lipofectamine 
RNAiMAX transfection reagent according to the 
manufacturer’s protocol (Life Technologies).
　 RL assay. The cells (2×104 cells) were plated 
onto 24-well plates and cultured for 48h after trans-
fection or infection.  The cells were harvested with 
Renilla lysis reagent (Promega,  Madison,  WI,  USA) 
and subjected to the RL assay.
　WST-1 cell proliferation assay. For the 
WST-1 assay,  the cells (4×103 cells) were plated 
onto a 96-well plate at 24h before transfection or 
infection.  The cells were subjected to a WST-1 cell 
proliferation assay at 48h after transfection or infec-
tion,  (Takara Bio,  Otsu,  Japan).
　Western blot analysis. The cells (1×105 
cells) were plated onto 6-well plates and cultured for 
48h after transfection or infection.  Preparation of the 
cell lysates,  sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE),  and immunoblotting 
were then performed as described previously [21].  
The antibodies for detection were Core (CP11;
Institute of Immunology,  Tokyo),  NS5A (Dr. T. 
Wakita,  National Institute of Infectious Diseases,  
Tokyo),  Rab13 (Atlas Antibodies,  Stockholm,  Sweden) 
and β-actin (AC-15; Sigma,  St. Louis,  MO,  USA).  
We performed an enhanced chemiluminescence assay 
(Perkin Elmer Life Science,  Wellesley,  MA,  USA) 
to detect immunocomplexes on the membranes.
　 HCV infection. RSc or D7 cells (2×104 cells) 
were plated onto a 24-well plate 24h before transfec-
tion or infection.  To evaluate the eﬀ ect of Rab13 in 
infection,  we ﬁ rst transfected the cells with siRNA 
and cultured them for 24h.  The cells were then inocu-
lated with supernatant from RSc cells containing 
reporter HCV-JFH-1 (JR/C5B/BX-2) at a multiplic-
ity of infection (MOI) of 0.2 [19].  After infection,  the 
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cells were cultured for 48h and subjected to an RL 
assay as described previously [19].  The JR/C5B/
BX-2 contains the RL gene in the ﬁ rst cistron follow-
ing the encephalomyocarditis virus-internal ribosomal 
entry site gene and the open reading frame (ORF) of 
HCV-JFH-1 in the second cistron.  To evaluate the 
eﬀ ect of Rab13 after infection,  we inoculated the cells 
with reporter HCV-JFH-1 at the MOI of 0.2 and cul-
tured the cells for 24h.  The cells were then trans-
fected with siRNA and cultured for 48h,  and sub-
jected to the RL assay.
　 Immunoﬂ uorescence staining. D7 cells (2×
104 cells) were plated onto a microscope slide and 
cultured for 48h after infection.  The cells were then 
washed in phosphate-buﬀ ered saline (PBS) and ﬁ xed 
using 3  paraformaldehyde in PBS for 15min at 
room temperature (RT).  The cells were washed 3 
times with PBS and permeabilized with 0.25  Triton 
X-100 for 10min at RT.  Next,  the cells were washed 
3 times with PBS and incubated in 1  bovine serum 
albumin (BSA) for 1h.  The cells were incubated with 
primary antibodies in 1  BSA overnight at 4℃.  The 
primary antibodies used were anti-Core and Rab13 
antibodies (1 : 150).
　 The cells were then washed 3 times with PBS and 
incubated with secondary antibodies for 30min at RT.  
Alexa ﬂ uor 488-conjugated goat anti-rabbit antibody 
and Alexa ﬂ uor 564-conjugated goat anti-mouse anti-
body were used as the secondary antibodies.  The cells 
were then stained with DAPI for 5min at RT.  DAPI 
was used for visualization of the nucleus.
　 Statistical analysis. Data represent the mean
±standard error obtained from at least triplicate 
experiments.  P-values were determined by Student’s 
t-test.  Signiﬁ cance was accepted at ＊p＜0.01.
Results
　 Rab13 is involved in HCV infection. Rab13 
regulates the endocytic recycling of the TJ-associated 
proteins CLDN1 and OCLN.  As CLDN1 and OCLN 
play key roles in HCV infection,  we examined whether 
Rab13 is required for HCV infection.  To do this,  we 
used an HCV-JFH-1 reporter assay system [19] and 
2 types of liver cells.  HuH-7-derived RSc cells and 
Li23-derived D7 cells are highly permissive cell lines 
for HCV infection [19].  To evaluate the eﬀ ect of 
Rab13 in HCV infection,  we transfected RSc and D7 
cells with siRNA targeting Rab13 before HCV infec-
tion (Fig.  1A).  The cells were inoculated with reporter 
HCV-JFH-1,  and we monitored the infection by mea-
suring the RL activity at 48h after infection.  The 
downregulation of Rab13 exhibited a weak inhibition 
of HCV infection in the RSc cells (Fig.  1B) and sig-
niﬁ cant inhibition in the D7 cells (Fig.  1C).  The 
downregulation of Rab13 did not exhibit cytotoxicity 
to the RSc or D7 cells until 2 nM of siRNA was used 
(Fig.  1B,  C).
　 The knockdown of Rab13 after HCV infection 
exhibited a marginal reduction of the Core in the RSc 
cells (Fig.  1D).  In the D7 cells,  the knockdown of 
Rab13 signiﬁ cantly reduced the Core in a dose-
dependent manner (Fig.  1E).  The inhibitory eﬀ ect on 
HCV infection by Rab13 suppression was stronger in 
the D7 cells than in the RSc cells.  These results sug-
gest that Rab13 is associated with the HCV infection.
　 The suppression of Rab13 after HCV infec-
tion had no eﬀ ect. We examined the eﬀ ect of the 
Rab13 after infection.  The cells were inoculated with 
reporter HCV-JFH-1 for 24h.  After infection,  the 
cells were transfected with siRNA and cultured for 
48h.  The eﬀ ect of Rab13 knockdown at post-infection 
was assessed using the RL assay (Fig.  2A).  The 
knockdown of Rab13 did not inhibit HCV proliferation 
in the RSc cells and exhibited marginal inhibition in 
the D7 cells at 2 nM of siRNA (Fig.  2B,  C).  The 
downregulation of Rab13 did not exhibit cytotoxicity 
to the RSc and D7 cells until 2 nM siRNA was used 
(Fig.  2B,  C).  There was no reduction of Core pro-
tein expression in the RSc or D7 cells until 2 nM of 
siRNA was used (Fig.  2D,  E).  These results suggest 
that Rab13 does not play a signiﬁ cant role in the HCV 
lifecycle after the viral entry step.
　 The suppression of Rab13 does not inhibit 
the replication of subgenomic HCV replicon.
We further examined whether Rab13 would inﬂ uence 
HCV RNA replication by using HCV-JFH-1 replicon-
harboring cells.  In this replicon system,  subgenomic 
HCV RNA could replicate but could not produce 
infectious virus.  The cells were transfected with 
siRNA and cultured for 48h (Fig.  3A).  The down-
regulation of Rab13 did not inhibit HCV RNA replica-
tion in the RSc or D7 cells (Fig.  3B,  C).  The lower 
concentration of siRNA exhibited enhancement of HCV 
RNA replication in both RSc and D7 cells.  The 
knockdown of Rab13 did not decrease the NS5A pro-
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tein expression (Fig.  3D,  E).  These results revealed 
that Rab13 did not inhibit the replication of subge-
nomic HCV RNA.
　 The downregulation of Rab13 inhibited HCV 
infection. We observed that Rab13 is required for 
HCV entry in D7 cells,  so we further examined 
whether Rab13 is required for HCV entry in D7 cells 
by confocal microscopy.  The D7 cells were trans-
fected with siRNA and infected with HCV-JFH-1 for 
48h.  The Rab13 and Core were observed in siCtrl-
treated cells (Fig.  4,  middle panels).  In contrast,  the 
siRab13-treated cells decreased the Core (Fig.  4,  
lower panels).  These results indicate that Rab13 is 
associated with the HCV infection step.
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Fig. 1　 Rab13 is involved in HCV infection.  (A) The experimental procedure used to identify the eﬀ ect of Rab13 in the HCV entry step 
and the schematic gene organization of reporter HCV-JFH-1.  The reporter HCV-JFH-1 contains the RL gene in the ﬁ rst cistron following 
the encephalomyocarditis virus-internal ribosomal entry site gene and the ORF of HCV-JFH-1 in the second cistron.  ΔC: 12 N-terminal 
amino acid residues of the Core.  (B) RSc cells were transfected with siRNA (0.25,  0.5,  1,  2nM) 24h before HCV infection.  The reporter 
HCV-JFH-1 was used as an inoculum after the removal of siRNA.  The cells were infected with the reporter HCV-JFH-1 and cultured for 
48h.  The inhibition of HCV infection was assessed by relative RL activity (relative light units: RLU).  The relative RL activity is shown as 
a percentage of the control value.  The cell viability was determined by WST-1 assay.  Bars: mean±standard deviation (SD) of triplicate 
data points.  (C) D7 cells were transfected with siRNA (0.25,  0.5,  1,  2nM) 24h before HCV infection.  The reporter HCV-JFH-1 was used 
as an inoculum after the removal of siRNA.  The cells were infected with the reporter HCV-JFH-1 and cultured for 48h.  The inhibition of 
HCV infection was assessed by RL activity.  The cell viability was determined by WST-1 assay.  (D) RSc cells were transfected with siRNA 
(0.25,  0.5,  1,  2nM) at 24h before HCV infection.  The authentic HCV-JFH-1 in the supernatant was used as an inoculum.  The cells were 
infected with HCV and cultured for 48h.  The expressions of Rab13 and Core were analyzed by immunoblotting using anti-Rab13 and anti-
Core antibodies.  β-actin was used as a control for the amount of protein loaded per lane.  (E) D7 cells were transfected with siRNA (0.25,  
0.5,  1,  2nM) at 24h before HCV infection.  The authentic HCV-JFH-1 in the supernatant was used as an inoculum.  The cells were 
infected with HCV and cultured for 48h.  The expressions of Rab13 and Core were analyzed by immunoblotting using anti-Rab13 and anti-
Core antibodies.  β-actin was used as a control for the amount of protein loaded per lane.
Discussion
　 The results of the present study demonstrated that 
Rab13 is required for the HCV entry step in the HCV 
lifecycle.  In particular,  the knockdown of Rab13 sig-
niﬁ cantly inhibited HCV infection and reduced the 
Core in D7 cells.  Rab13 did not support the other 
steps.
　 It is likely that membrane transport participates in 
the lifecycle of HCV.  It was reported that Rab pro-
teins are essential host factors for the HCV lifecycle,  
and that Rab proteins are important for HCV RNA 
replication and viral assembly [12-15].  However,  we 
were unable to ﬁ nd any prior study of Rab regarding 
the HCV entry step.  We focused here on Rab13,  
which regulates TJ assembly and the membrane traﬃ  c 
[16,  17].  The TJ plays a key role in HCV’s entry into 
cells.  Rab13 regulates the endocytic recycling of 
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Fig. 2　 The suppression of Rab13 after HCV infection had no eﬀ ect.  (A) The experimental procedure for determining the eﬀ ect of Rab13 
in the HCV entry step and the gene organization of reporter HCV-JFH-1.  (B) RSc cells were infected with the reporter HCV-JFH-1 before 
the transfection of siRNA,  and 24h after infection,  the cells were transfected with siRNA (0.25,  0.5,  1,  2nM) and cultured for 48h.  The 
inhibitory eﬀ ect on HCV proliferation after infection was assessed by relative RL activity,  which is shown as a percentage of the control.  
The cell viability was determined by WST-1 assay.  Bars: the mean±SD of triplicate data points.  (C) D7 cells were infected with the 
reporter HCV-JFH-1 before the transfection of siRNA and then cultured for 24h.  After infection,  the cells were transfected with siRNA 
(0.25,  0.5,  1,  2nM) and cultured for 48h.  The inhibitory eﬀ ect on HCV proliferation after infection was assessed by relative RL activity.  
The cell viability was determined by WST-1 assay.  (D) RSc cells were infected with authentic HCV-JFH-1 and cultured for 24h.  After 
infection,  the cells were transfected with siRNA (0.25,  0.5,  1,  2nM) and cultured for 48h.  The expressions of Rab13 and Core were 
analyzed by immunoblotting using anti-Rab13 and anti-Core antibodies.  β-actin was used as a control for the amount of protein loaded per 
lane.  (E) D7 cells were infected with authentic HCV-JFH-1 virion and cultured for 24h.  After infection,  the cells were transfected with 
siRNA (0.25,  0.5,  1,  2nM) and cultured for 48h.  The expressions of Rab13 and Core were analyzed by immunoblotting using anti-Rab13 
and anti-Core antibodies.  β-actin was used as a control for the amount of protein loaded per lane.
TJ-associated proteins,  CLDN1 and OCLN,  which 
are HCV entry receptors.
　 We ﬁ rst investigated whether the downregulation 
of Rab13 would inhibit HCV infection by using 2 dis-
tinct hepatoma cell lines,  HuH-7 and Li23.  The 
results indicated that the downregulation of Rab13 by 
siRNA inhibited HCV infection (Figs.  1,  4).  Rab13 
may be required for HCV infection,  but it was not 
essential for HCV RNA replication (Figs.  2,  3).
　 The siRab13 treatment in the Li23-derived D7 
cells had a greater inhibitory eﬀ ect against HCV infec-
tion compared to that in the HuH-7-derived RSc cells.  
We reported diﬀ erential gene expressions between 
Li23 and HuH-7 cells [22].  For example,  the expres-
sion of Rab escort proteins (REPs) is higher in Li23 
cells than in HuH-7 cells.  REPs are one of the host 
components for the geranylgeranylation of Rabs.  The 
REP consists of REP-1 and REP-2,  and interestingly,  
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Fig. 3　 The suppression of Rab13 does not inhibit the replication of subgenomic HCV replicon.  (A) The experimental procedure used to 
determine the eﬀ ect of Rab13 on HCV RNA replication.  The gene organization of subgenomic HCV replicon is described in the Materials 
and Methods section.  (B) Subgenomic HCV-JFH-1 RNA (JRN/35B) replicating RSc cells were transfected with siRNA (0.25,  0.5,  1,  2nM) 
for 48h.  The relative RL activity for HCV RNA replication is expressed as a percentage of the control.  Bars: mean±SD of triplicate data 
points.  (C) Subgenomic HCV-JFH-1 RNA (JRN/35B) replicating D7 cells were transfected with siRNA (0.25,  0.5,  1,  2nM) and cultured 
for 48h.  The relative RL activity for HCV RNA replication is expressed as a percentage of control.  (D) Subgenomic HCV-JFH-1 RNA 
(JRN/35B) replicating RSc cells were transfected with siRNA (0.25,  0.5,  1,  2nM) for 48h.  The expressions of Rab13 and NS5A were 
analyzed by immunoblotting using anti-Rab13 and anti-NS5A antibodies.  β-actin was used as a control for the amount of protein loaded per 
lane.  (E) Subgenomic HCV-JFH-1 RNA (JRN/35B) replicating D7 cells were transfected with siRNA (0.25,  0.5,  1,  2nM) and cultured for 
48h.  The expressions of Rab13 and NS5A were analyzed by immunoblotting using anti-Rab13 and anti-NS5A antibodies.  β-actin was used 
as a control for the amount of protein loaded per lane.
REP-1 is expressed in the Li23 cell line but not in the 
HuH-7 cell line (unpublished data).  The lack of the 
REP-1 may aﬀ ect the diﬀ erent inhibitory eﬀ ects 
against HCV infection with the siRab13 treatment 
between the 2 cell lines.
　 We reported that the OCLN expression in Li23-
derived D7 cells is two times higher than in HuH-7-
derived RSc cells and that the CLDN1 expression in 
HuH-7-derived RSc cells is 1.5 times higher than in 
Li23-derived D7 cells [19].  The diﬀ erent expression 
balance may aﬀ ect the HCV infection via Rab13.  The 
diﬀ erent expressions of unknown host factors regard-
ing Rab modiﬁ cation and HCV proliferation may have 
inﬂ uenced the results of the present experiments with 
siRab13.  To clarify this issue,  further studies are 
needed.
　 Recent studies show that HCV entry requires 
several host factors.  The TJ-associated proteins 
CLDN1 and OCLN go and return between the TJs and 
the cytoplasm.  These proteins do not interact with the 
HCV particles.  CLDN1 and OCLN play roles in the 
post-attachment step by interacting with HCV 
E2-CD81 [23,  24].  The inhibition of HCV infection 
by the downregulation of Rab13 is thus not due to the 
direct interaction with the HCV particles.
　 It was recently reported that protein kinase A 
(PKA) signaling was required for HCV entry.  PKA 
signaling promoted the CD81-CLDN1 interaction in 
TJ.  Inhibition of PKA activity induced a reorganiza-
tion of CLDN1 from TJs to the cytoplasm [25].  In 
another study,  Rab13 interacted with PKA and was 
implicated in TJ assembly [26].  The active-form 
Rab13-GTP bound to PKA and inhibited phosphory-
lation,  resulting in the localization of CLDN1 in the 
cytoplasm,  whereas the inactive-form Rab13-GDP did 
not bind to PKA,  resulting in recycling CLDN1 to the 
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Rab13 HCV Core MergeNucleus
Mock
siCtrl
siRab13
Fig. 4　 Rab13 is required for HCV infection.  D7 cells were transfected with siCtrl (middle panels) or siRab13 (lower panels) (100nM) at 
24h before HCV infection.  The cells were mock-infected (upper panels) or infected with authentic HCV-JFH-1 at a MOI of 2 (middle and 
lower panels) and cultured for 48h.  The cells were then stained with HCV Core (red) and Rab13 (green) antibody and observed by confocal 
microscopy.
TJ.  Collectively,  these results raise the possibility 
that the inhibition of HCV infection by the down-regu-
lation of Rab13 is related to PKA signaling.
　 In conclusion,  our present ﬁ ndings demonstrate 
that Rab13 is involved in the HCV entry step.
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